Navigation Links
Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/3/2008

FAIRFIELD, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced that Dr. Roger G. Berlin, Chief Executive Officer of Arno, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 2:00 PM EST in the Kennedy I room at the New York Palace Hotel in New York City. Dr. Berlin will provide a company overview and update on the status of Arno's current clinical development programs.

The presentation will be webcast live and can be accessed by visiting the Investor Relations second of Arno's website at http://www.arnothera.com. The webcast will be archived for 90 days.

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead compound is AR-67, a novel third-generation camptothecin analogue entering Phase II clinical development in patients with various forms of cancer. Arno has completed enrollment in a single agent, ascending dose, Phase I clinical study of AR-67 in patients with advanced solid tumors. AR-67 has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway that is undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways also undergoing IND-enabling studies. Arno is actively pursuing additional compounds to expand its portfolio. For more information on Arno please visit http://www.arnothera.com.

Forward-Looking State
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. United Therapeutics Reports Third Quarter 2008 Financial Results
4. Arete Therapeutics Bolsters Management Team
5. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
6. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
7. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
8. Nektar Therapeutics to Webcast R&D Day on November 12th
9. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
10. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
11. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 ... of the "Global DNA Diagnostics Market (Product ... Size, Share, Global Trends, Company Profiles, Demand, Insights, ... - 2020" report to their offering. ... Market (products, applications, techniques, end users and Geography) ...
(Date:10/22/2014)... Involution Studios , a healthcare software design ... Understanding Ebola . The goal of the ... follow informative tool for anyone wanting to know more ... , "As the news has spread in all directions ... not only a healthcare crisis with global impact, but ...
(Date:10/22/2014)... According to new market research ... (Consulting, Integration, Deployment & Support), by Service Model ... Private, Others (Hybrid & Community)) - Global Forecast ... the Cloud Professional Services Market into various sub-segments ... It also identifies the drivers and restraints for ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... ... Screener for High Content Screening analysis. , ... (PRWEB) January 11, 2010 -- Genedata, a leading provider of advanced software solutions ... Genedata Screener has experienced unprecedented industry adoption with 7 out of the ...
... DUSSELDORF, Germany, January 11 , ... - Important Step in the Worldwide Development of Medical ... set up a new facility for medical plastic,systems in Indaiatuba (Brazil). ... of a long-term cooperation agreement with Novo Nordisk,components will be produced ...
... , , , , , , ... - Novel SNPs Modulate ECG Measurements Including Heart Rate, Two are ... , Scientists at deCODE genetics today report the ... human genome,(SNPs) that are involved in modulating the electrical impulses that govern,the ...
Cached Biology Technology:Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 2Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 3Gerresheimer Sets up New Production Facility for Insulin Pen Systems in Brazil 2deCODE Finds Genetic Factors Impacting Key Clinical Measurements of Heart Activity and Disease Risk 2deCODE Finds Genetic Factors Impacting Key Clinical Measurements of Heart Activity and Disease Risk 3deCODE Finds Genetic Factors Impacting Key Clinical Measurements of Heart Activity and Disease Risk 4
(Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... Mass. (April 13, 2009) Boston College Chemistry Professor ... Guggenheim Memorial Foundation Fellowship for his theoretical studies of ... to be among the 180 scientists, artists and scholars ... U.S. chemist to receive a Guggenheim this year, Mohanty ...
... Society (ACS) Weekly PressPac from the Office of Public ... and Chemical & Engineering News.,Please credit the individual journal ... this information. PressPac Archive: http://portal.acs.org/portal/PublicWebSite/pressroom/presspacs/CTP_006742 ... RELEASE, Solving the mystery of what puts sperm "in ...
... The small flowering plant Arabidopsis is widely ... A member of the mustard family, Arabidopsis ... genome, a compact size, a life-cycle of about only six ... production. Now Daniel Gallie , a professor of ...
Cached Biology News:American Chemical Society Weekly PressPac -- April 8, 2009 2American Chemical Society Weekly PressPac -- April 8, 2009 3American Chemical Society Weekly PressPac -- April 8, 2009 4American Chemical Society Weekly PressPac -- April 8, 2009 5American Chemical Society Weekly PressPac -- April 8, 2009 6American Chemical Society Weekly PressPac -- April 8, 2009 7American Chemical Society Weekly PressPac -- April 8, 2009 8American Chemical Society Weekly PressPac -- April 8, 2009 9American Chemical Society Weekly PressPac -- April 8, 2009 10American Chemical Society Weekly PressPac -- April 8, 2009 11UC Riverside biochemist to study how crops can increase protein production 2
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... Human, Assay, 96 wells. ELISA.Specific for ... complexed MMP-3. No cross-reactivity with MMP-1, -2, ... for use with cell culture supernatant, serum, ... -15 to -30 C. Category: Drug ...
... Steady gravity-fed delivery of buffer and ... perfusion. Rat version. In Vivo Manual ... gravity-fed delivery of buffer and fixative ... to setup, use and clean--Complete system ...
... Single-cell and patch delivery Removable / ... Very small dead volume , Vacuum ... 250 and 100 micron delivery tips - removable ... Available in 4, 8, and 16 channels. Specify ...
Biology Products: